Press Releases
EG-301’s Phase II Clearance Underscores AI’s Strategic role in Efficient Drug Development
The advancement of EG-301 underscores a reverse-translational approach empowered by Evergreen’s AI-driven clinical models, which enable precise indication prioritization and mechanistic insight.
Another Evergreen Me-Only Drug Cleared by the FDA for Phase II Clinical Trial
On February 4, 2022, Evergreen Therapeutics announced that the IND for an oral drug for the treatment of dry macular degeneration with independent intellectual property rights, EG-301, was cleared by the US FDA to proceed to its phase II clinical trial.
FDA Experts Association Holds Autumn Gathering in Washington DC
In celebration of the “Golden Autumn” season, the FDA Experts Association hosted its North America Golden Autumn Reception on October 16, 2021, in North Bethesda, Maryland.
Preclinical studies of EG-301 demonstrate an acceptable safety profile and preliminary in vivo efficacy
Evergreen Therapeutics announced that EG-301, an oral small-molecule candidate developed for dry age-related macular degeneration (dry AMD), has demonstrated both an acceptable safety profile and preliminary efficacy in attenuating disease progression in preclinical animal studies.
Evergreen Therapeutics Enrolls First Patient in U.S. Phase II Trial for Cognitive Impairment Drug EG-501
Evergreen Therapeutics recently announced that the first patient has been enrolled in its Phase II clinical trial in the United States for its investigational drug EG-501.
